PharmaBlock Sciences Nanjing Inc Class A (300725) — Net Asset Quality Index
PharmaBlock Sciences Nanjing Inc Class A (300725) has a Net Asset Quality Index of 86.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥6.39 Billion minus total liabilities of CN¥891.08 Million yields net assets of CN¥5.50 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read PharmaBlock Sciences Nanjing Inc Class A (300725) total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
PharmaBlock Sciences Nanjing Inc Class A Net Asset Quality Index Over Time (2013–2025)
This chart shows how PharmaBlock Sciences Nanjing Inc Class A's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 86.1%, representing net assets of CN¥5.50 Billion against total assets of CN¥6.39 Billion CNY. For live market cap and overall valuation, see PharmaBlock Sciences Nanjing Inc Class A (300725) market capitalisation.
Annual Net Asset Quality Index for PharmaBlock Sciences Nanjing Inc Class A (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check 300725 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 85.8% | CN¥6.30 Billion | CN¥7.34 Billion | CN¥1.04 Billion | ▲ +25.3 pp |
| 2024 | 60.5% | CN¥2.99 Billion | CN¥4.94 Billion | CN¥1.95 Billion | ▲ +5.0 pp |
| 2023 | 55.5% | CN¥2.83 Billion | CN¥5.10 Billion | CN¥2.27 Billion | ▲ +0.8 pp |
| 2022 | 54.7% | CN¥2.66 Billion | CN¥4.86 Billion | CN¥2.20 Billion | ▼ -20.3 pp |
| 2021 | 74.9% | CN¥2.63 Billion | CN¥3.51 Billion | CN¥879.21 Million | ▼ -3.2 pp |
| 2020 | 78.1% | CN¥1.89 Billion | CN¥2.43 Billion | CN¥530.57 Million | ▲ +6.1 pp |
| 2019 | 72.0% | CN¥740.87 Million | CN¥1.03 Billion | CN¥288.27 Million | ▼ -6.8 pp |
| 2018 | 78.8% | CN¥599.73 Million | CN¥761.16 Million | CN¥161.43 Million | ▼ -10.0 pp |
| 2017 | 88.8% | CN¥503.59 Million | CN¥567.40 Million | CN¥63.80 Million | ▲ +3.8 pp |
| 2016 | 85.0% | CN¥254.15 Million | CN¥299.15 Million | CN¥45.00 Million | ▼ 0.0 pp |
| 2015 | 85.0% | CN¥146.56 Million | CN¥172.48 Million | CN¥25.92 Million | ▼ -0.9 pp |
| 2014 | 85.8% | CN¥87.18 Million | CN¥101.56 Million | CN¥14.38 Million | ▲ +3.4 pp |
| 2013 | 82.4% | CN¥70.16 Million | CN¥85.13 Million | CN¥14.97 Million | — |